Mizuho Discusses Biogen (BIIB) Seizure Patient
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Mizuho Discusses Biogen (BIIB) Seizure Patient
December 9, 2016 1:01 PM EST
Biogen (NASDAQ: BIIB) active on headlines:one patient had treatment-related seizure, loss of pulse.
...
More
December 9, 2016 8:15 AM EST
Health Canada has approved ZINBRYTA (daclizumab beta), a new once-monthly, self administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis (RRMS), who have had an inadequate response to, or are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV)... More
December 9, 2016 7:20 AM EST
By Lewis Krauskopf
NEW YORK (Reuters) - Major U.S. stock indexes powered to another day of fresh record highs on Friday, with the S&P 500 ending the week up 3 percent, as investors bid up shares in sectors that have lagged in the month-long rally since Donald Trump's presidential election.
The benchmark S&P 500 registered a record high for the third straight session, while the Dow and Nasdaq also hit new highs. The Dow recorded a fifth straight week of gains.
Trump's expected agenda of economic stimulus and reduced taxes and regulations has particularly fueled financial... More
December 9, 2016 6:34 AM EST
Baird analyst Brian Skorney raised his price target on Biogen (NASDAQ: BIIB) to $309.00 (from $284.00) following additional sola details. The firm stopped short of upgrading the stock, however, and maintained a Neutral rating.
Skorney commented, "Lilly reported additional quantitative results from the Phase 3... More
December 9, 2016 6:29 AM EST
BMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
December 8, 2016 3:03 PM EST
(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
